Catherine H. Marshall, MD, MPH, of Johns Hopkins Hospital, discusses phase II trial results on bicalutamide, an oral antiandrogen used to treat prostate cancer. Bicalutamide may be helpful in downregulating the TMPRSS2 and ACE proteins needed for the SARS-CoV-2 virus; upregulating estradiol to help resolve acute lung injury; and improving outcomes in patients with COVID-19 infection (Symposium 4).
Karen E. Knudsen, MBA, PhD, of the Sidney Kimmel Cancer Center at Jefferson Health, summarizes a panel she moderated on telehealth, which included discussion of usage in urba...
Gabriella Pravettoni, PhD, of the University of Milan, discusses the need for tailored psychological interventions to take care of oncologists, health-care workers, and patie...
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and the President of AACR, discusses this special conference that fo...
Jessica Y. Islam, PhD, MPH, of the UNC Lineberger Comprehensive Cancer Center, discusses findings from the COVID-19 Impact Survey, which showed that cancer survivors are adhe...
Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, talks about a panel she moderated in which speakers discussed the importance of communicating with patients ...